This paper is in the following e-collection/theme issue:

Viewpoints and Perspectives (6) Mobile Health (mhealth) (2982) Mobile Apps for Cancer Care and Cancer Prevention and Screening (210) mHealth for Data Collection and Research (981) mHealth for Symptom and Disease Monitoring, Chronic Disease Management (1428) Innovations and Technology for Cancer Prevention and Screening (150) Wearable Devices and Sensors (903) mHealth for Diagnosis (63)

Published on in Vol 10 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/52577, first published .
“Notification! You May Have Cancer.” Could Smartphones and Wearables Help Detect Cancer Early?

“Notification! You May Have Cancer.” Could Smartphones and Wearables Help Detect Cancer Early?

“Notification! You May Have Cancer.” Could Smartphones and Wearables Help Detect Cancer Early?

Authors of this article:

Suzanne E Scott1 Author Orcid Image ;   Matthew J Thompson2 Author Orcid Image
Article Authors Cited by Tweetations (11) Metrics

    Viewpoint

    1Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom

    2Department of Family Medicine, University of Washington, Seattle, WA, United States

    Corresponding Author:

    Suzanne E Scott, BSc, MSc, PhD

    Centre for Cancer Screening, Prevention and Early Diagnosis

    Wolfson Institute of Population Health

    Queen Mary University of London

    Charterhouse Square

    London, EC1M 6BQ

    United Kingdom

    Phone: 44 2078823550

    Email: suzanne.scott@qmul.ac.uk


    This viewpoint paper considers the authors’ perspectives on the potential role of smartphones, wearables, and other technologies in the diagnosis of cancer. We believe that these technologies could be valuable additions in the pursuit of early cancer diagnosis, as they offer solutions to the timely detection of signals or symptoms and monitoring of subtle changes in behavior that may otherwise be missed. In addition to signal detection, technologies could assist symptom interpretation and guide and facilitate access to health care. This paper aims to provide an overview of the scientific rationale as to why these technologies could be valuable for early cancer detection, as well as outline the next steps for research and development to drive investigation into the potential for smartphones and wearables in this context and optimize implementation. We draw attention to potential barriers to successful implementation, including the difficulty of the development of signals and sensors with sufficient utility and accuracy through robust research with the target group. There are regulatory challenges; the potential for innovations to exacerbate inequalities; and questions surrounding acceptability, uptake, and correct use by the intended target group and health care practitioners. Finally, there is potential for unintended consequences on individuals and health care services including unnecessary anxiety, increased symptom burden, overinvestigation, and inappropriate use of health care resources.

    JMIR Cancer 2024;10:e52577

    doi:10.2196/52577

    Keywords

    wearables; early diagnosis; cancer; challenges; diagnosis; wearable; detect; detection; smartphone; cancer diagnosis; symptoms; monitoring; monitor; implementation; anxiety; health care service; mobile phone 


    There is growing use of smartphones, wearables, and other technologies in health and wellness, either as consumer products or medical devices. The National Health Service (NHS) Long Term Plan [1] anticipates that in 10 years, people will have “the option for their physiology to be effortlessly monitored by wearable devices. People will be helped to stay well, to recognize important symptoms early, and to manage their own health, guided by digital tools.” Similarly, in 2020, the US Food and Drug Administration (FDA) launched a Digital Health Innovation Action Plan to encourage digital health innovation as “digital health technologies can empower consumers to make better-informed decisions about their own health and provide new options for facilitating prevention, early diagnosis of life-threatening diseases, and management of chronic conditions outside of traditional care settings” [2]. Wearables are devices that can be worn to detect and monitor biometric data such as heart rate, blood oxygen saturation, sleep pattern, or temperature while the wearer continues their normal routines. A further category of wearables involves skin patches used to measure biochemical signals (ie, glucose) on a continuous basis that are increasingly being considered as a standard of care for individuals with certain conditions (eg, diabetes) [3]. While most wearables have been wrist-worn devices, similar physiologic signals are now being generated from other devices such as rings or earbuds. Smartphones are also increasingly being used for health and wellness; they have the advantage of far higher use (compared with wearables), and a growing array of different sensors are routinely embedded. Could smartphones and wearables help detect cancer and, importantly, detect cancer earlier in its disease course when it is more likely to be localized and with a better prognosis? This paper provides an overview of the scientific rationale as to why these technologies could be valuable for early detection of cancer, the potential barriers to successful implementation, and the next steps for research and development.


    While national cancer screening programs offer the opportunity to detect cancer or precancerous lesions in asymptomatic individuals, routine screening currently only accounts for the minority (<10%) of cancer diagnoses [4,5]. The predominant route to a cancer diagnosis is symptomatic presentation to ambulatory care. Thus, the diagnosis of cancer heavily relies on patients’ ability to notice and attend to relevant bodily changes and their decision to consult a health care professional [6,7]. However, noticing relevant bodily changes is challenging given the multiple subtle changes that may signal cancer among the plethora of daily bodily changes; fluctuations of normal bodily processes; self-limiting, transient symptoms; and the presence of chronic conditions. The signal-to-noise ratio is weak. This issue is exacerbated by individuals’ limited ability to accurately interpret vague bodily changes, many of which can be associated with cancer (eg, fatigue, weight loss, and stomach upset). This is because our awareness, attention, and interpretation are affected by expectations; emotions; beliefs; and biological, environmental, sociodemographic, and contextual factors [8-11]. Furthermore, symptoms may evolve very slowly over time, making it difficult to notice subtle changes. It is reported that the predominant risk factor for delay in seeking help following the detection of cancer symptoms is the “lack of interpretation by patients of the serious nature of their symptoms” [12].

    Smartphones and wearable technologies have the potential to facilitate the detection and tracking of bodily changes that might otherwise be dismissed or interpreted as only needing self-medication rather than the attention of a health care professional. There is emerging data about early, subtle signs of cancer, and some of these may be amenable to detection by electronic sensors and monitoring of behavior (see Table 1).

    Table 1. Potential signals of cancer that can be measured using sensors in smartphones or wearables.
    Sensors currently available on some smartphones or wearablesExamples of signals for health features that could be related to cancer
    Audio signals from microphones [13]
    • Changes in cough and breathing difficulty (associated with lung cancer) [14]
    • Changes in voice such as hoarseness (associated with head and neck cancer and lung cancer) [14]
    GPS location tracking and activity tracking [15]
    • Reduced activity resulting from fatigue (associated with multiple cancers) [14]
    Image capture and analysis [16-18]
    • Anemia detected from images of the skin or eyes (associated with multiple cancers) [19]
    • Jaundice detected from images of the skin or eyes (associated with pancreatic cancer) [20]
    • Changes in skin lesions (associated with skin cancer) [14]
    Temperature measurement [21]
    • Rise in temperature (associated with pancreatic cancer) [22]
    Body composition using image analysis and electro dermal activity [23]
    • Weight loss (associated with multiple cancers) [14]
    Photoplethysmogram [24]
    • Anemia (associated with multiple cancers) [19]

    Sensors could allow the detection of changes prior to them being noticed or interpreted as symptoms, for example, a reduction in activity prior to fatigue or changes in food consumption prior to weight loss. There is recent evidence that monitoring day-to-day purchases could detect an increase in over-the-counter pain and indigestion medication 8 months prior to ovarian cancer diagnosis [25]. This demonstrates how tracking and monitoring change over time could allow insight into emerging disease. This is particularly useful for clinicians working in health care settings with limited time and resources and where cancer is a relatively rare occurrence among the burden of other diseases. In addition to the detection of signals, smartphones and wearables could alert the user to the need for health care consultation and provide an endorsement to seek care. This could overcome the commonly reported barrier to presentation (“concern about bothering the doctor”) that arises when there is uncertainty about the need for care [26-28].


    Overview

    Despite the promise of smartphones and wearables for early detection of cancer, there are several hurdles to implementation that require attention. Key barriers to success are outlined here, alongside suggestions for how these may be addressed with future research.

    Signals and Sensors With Accuracy and Utility

    The use and adoption of smartphones and wearables in this context require robust research into the selection of a signal, the development of sensors, and the generating evidence of accuracy and utility of those sensors in the real world. This includes identifying physiologic (or emerging pathophysiologic) signals that are most predictive of cancer, determining how often these need to be collected, and elucidating what other data would add precision to results (eg, age, risk factors, and presence of symptoms). For technology developers, sensors are usually designed and prioritized for a number of potential applications, mainly targeting overall health and wellness rather than diagnostic capabilities per se. Prioritizing these research and development efforts for cancer detection specifically over and above other priorities could be challenging to justify for business development reasons. Relatedly, the original intended commercial purpose of existing sensors may not have been connected to cancer detection. To make headway in this field of research, technology developers and device users will need to be willing to provide access to data for research. General Data Protection Regulation allows device users to share their data with third-party organizations under the right to portability. Developing systems to facilitate data sharing, in formats compatible with health data, could allow the generation of new data sets to signal cancer risk. This will prevent duplication of effort and maximize the use of existing data for public benefit.

    While initial evidence on the accuracy of a sensor to detect a given health signal could involve case-control studies (eg, individuals recently diagnosed with cancer and matched controls), subsequent research would likely require large prospective cohorts. Further, given the weak signal-to-noise ratio, it is likely that signals from wearables or smartphones alone might lack sensitivity or specificity. Therefore, research that combines signals from wearables or smartphones with other digital sources of data (eg, symptoms recorded in health records and initial laboratory tests in primary care) will almost certainly be needed to demonstrate sufficient accuracy and utility in target populations. This was recently highlighted in a systematic review [29] of artificial intelligence technologies for skin cancer detection. Despite an abundance of digital products, the review highlighted that there has been very little testing in low-prevalence populations and limited data on the use of lower-quality images (eg, taken by patients or family physicians or using lower-quality phones), and as such, widespread adoption into practice has been limited [30].

    Innovators also need to consider (and test) whether these new digital tools should and could detect more than 1 type of cancer (or detect other potentially important nonmalignant diseases; eg, cirrhosis in individuals with jaundice or depression in individuals with weight loss). Other considerations include who the target group is (eg, all adults or only those at higher risk of developing cancer), at what point in time (eg, certain age), and at what periodicity that group should begin using this technology for the detection of cancer. Further, it is well documented that symptom monitoring increases selective attention to the body, resulting in increased symptom reporting [31]; thus, the monitoring of symptoms could result in increased symptom burden. Development and testing need to determine the extent to which the monitoring of activity, symptoms, and other signals changes the outputs of those measurements [32,33].

    Regulatory Challenges

    Given the burden involved in fulfilling regulatory approvals for diagnostic devices, many smartphone technologies and wearables that could potentially have value for cancer detection will instead be introduced as products for overall health and wellness management. As the field expands, more guidance and standards for digital health tools are being introduced to ensure that they are not only safe and effective but also adoptable by the health care system [34]. For example, the recent UK National Institute of Health and Care Excellence (NICE) evidence standards framework [35] is intended to ensure new digital health technologies are clinically effective and offer value to the health care system. The framework includes standards concerning safety, quality, acceptability, bias mitigation, data practices, professional oversight, credibility with health professionals, safeguarding assurances, scalability, as well as evidence of real-world performance and use. In some countries, consumer protection regulations also determine standards that certain wellness features (eg, step counting and heart rate measurement) need to fulfill, even though these are not regulated medical devices. As specified in the CanTest framework for early cancer detection [36], research and development will benefit from this early specification of the criteria (eg, target product profiles) needed for successful digital products for cancer detection [37-39].

    Ensuring Equity

    A key issue of wearables and smartphone technologies is the potential for new innovations to exacerbate inequalities in cancer outcomes. Sociodemographic factors such as household income, age, level of education, and gender have been found to influence the use of mobile health (mHealth) technology [40-44] and there is “a real risk that the increased use of digital technologies will make care experiences and outcomes worse for some people (or communities)” [45]. Development of wearables and smartphone technologies for cancer detection should be conducted with an equity lens to focus on the views and needs of those living or working in more deprived areas and those at risk of lower health literacy (eg, those with lower educational level, older age, lower income, and ethnic minority groups) [46,47], so that cultural attitudes toward the use of technology, affordability, and access can be a focus in their development. Inclusion and diversity within the development and testing of sensors are vital so that products are not biased and work equally regardless of skin color or other physiological differences [29]. Affordability is also a crucial point. Even though smartphone use is extensive [48] in both higher- and lower-income countries, the availability and quality of sensors differ across brands and models of smartphones. Wearable devices have far lower penetration in most high-income countries and lower still in those individuals with lower socioeconomic status. If accurate and reliable sensors are only available on high-end devices, then the net result will be inequitable outcomes. The consideration of a reverse innovation approach may be useful here if it is possible, to focus testing on inexpensive, easy-to-use products that can be rolled out at scale.

    Acceptability and Adherence

    Crucial to the successful implementation of any innovation is early insight into the user perspective, including acceptability, uptake, and correct use by the intended target group [49-51]. Yet, this consultation is often omitted or occurs too late in mHealth implementation, resulting in user burden; technical issues; poor designs; and ultimately the lack of uptake, adherence, and impact of the technology [49,52-54]. Indeed, there is currently an absence of research on user perspectives on wearables and smartphone technologies for the detection of cancer. While key issues such as cost, motivation, comfort, ease of use, trust in data use, visibility, and interpretability of data are applicable across the spectrum of wearables and smartphone technologies in health [40,55], there may be additional, specific challenges for using these innovations for the detection of cancer.

    In this context, acceptability also pertains to individuals’ willingness to share their data from smartphones and wearables with researchers, medical professionals, or private companies. Willingness to share data from wearables was reported to be lower than that for other commercial data [56]. Less than 15% (n=65) of survey respondents aged 60 years and older were willing to share wearable device data with academic research institutions and only 40% (n=423) of those aged 18-59 years were willing to do so. Trust in organizations and worry about data misuse have been shown to be a key factor in people’s willingness to share commercial data for health research [56]. Ensuring clear and transparent data use and data-sharing policies is vital for success. There are real concerns about the misuse of data, commercialization, and access to data by unauthorized people [57]. While data sharing is an essential component in the use of smartphones and wearables for cancer detection, data protection is equally as vital.

    In research studies of wearables, dropout rates can be up to 44% [40], and nonadherence to wearing devices for the study duration can be up to 50% [58,59]. Nonadherence is likely to be even higher in people with preexisting comorbidities and for technologies requiring long-term engagement, as may be needed for cancer detection to track signals over time. Balancing the advantages and disadvantages of continuous versus intermittent measurements at certain intervals should be a key consideration.

    It is, therefore, essential to investigate user perspectives in parallel with the development and potential future deployment of wearables and smartphone technologies for cancer detection. This also includes encompassing the views of clinicians who are involved in the ongoing surveillance and care of those with a history of cancer and would inevitably be involved in shared decision-making on the potential implementation of such technologies and, crucially, the ongoing clinical management of individuals whose sensors indicate signals of possible cancer. In general, primary care clinicians have not typically been deeply engaged in the implementation of other consumer-grade or regulated medical devices; understanding from these clinicians’ viewpoint on how they could use information from smartphones and wearables within their clinical care pathways is critical to any adoption [60].

    Unintended Consequences on Individuals and Health Care Services

    The exciting potential of wearable technologies for cancer detection must be considered alongside the possible negative consequences. As seen with other new developments in cancer detection, given the overall very low prevalence of cancer, even tests with very high specificity will lead to a large number of individuals with false positives. The subsequent need for investigation and resources needed to differentiate those with false versus true positives (ie, do have cancer) could be considerable. For the majority of individuals, this could lead to huge risks of overinvestigation and inappropriate use of health care resources [61]. For cancer detection specifically, we can anticipate a far higher potential for wearables and smartphone technologies to generate anxiety than for other conditions (eg, detection of sleep apnea, or detection of irregular heartbeat), especially among those already fearful of cancer recurrence. This is particularly relevant to the question of how “results” should be delivered to users, what support would be needed at that time, and whose responsibility this would be. On the other hand, wearable use may lead to a false sense of reassurance, leading to a lower perceived need to attend cancer screening or respond to symptoms (eg, “my wearable says I am healthy...there is no need to see my doctor”). This is similar to when a negative cancer screening test result can overly reassure patients and affect subsequent decisions to seek care [62]. These issues about the psychological and behavioral impact of smartphone technologies and wearables to detect cancer remain unexplored and need focused behavioral science research.


    For most cancers, the time from detecting a bodily change to interpreting that change as requiring the advice of a health care professional constitutes a substantial proportion of the time prior to diagnosis. The detection of cancer remains one of the most prominent priorities of many health systems, governments, and private and public research funders [63,64], and “leaving no stone unturned” in technologies that could potentially improve early detection is a priority. The rapid advances in the hardware (ie, sensors) and software embedded in smartphones and wearables offer exciting and potentially untapped opportunities to detect early warning signs of cancer that may otherwise be missed. The research and development needed to advance this field include the selection of appropriate signals and development of effective sensors followed by robust clinical research into accuracy in real-world settings. This relies on the up-front specification of the target groups and their needs. Target product profiles should be developed specifically for cancer detection technologies, and innovators should consult these and consider regulatory challenges early in the process of development, to design products in line with the requirements of individuals, clinicians, and health care systems. The potential negative consequences of this type of technology should be acknowledged and investigated up-front, and mitigations should be incorporated into the design and implementation strategies. To avoid exacerbation of inequalities in cancer outcomes, research into the use of wearables and smartphone technologies in cancer detection should be done with an equity lens to ensure that products are developed for those who have poorer health outcomes, for whom new innovations could have the most impact. There is a need for research to explore the patient, public, and health care perspectives about the use of smartphones and wearables for the early detection of cancer while this field is in its infancy, so that these can be incorporated into product design to optimize acceptability and adherence, avoid unintended consequences, and maximize the chance of their success.

    Acknowledgments

    SES is supported by Barts Charity (G-001520; MRC&U0036). MJT received no funding in support of this manuscript.

    Authors' Contributions

    SES and MJT conceived the work that led to the submission. SES drafted the manuscript. SES and MJT revised the manuscript and approved the final version.

    Conflicts of Interest

    SES declares no conflicts of interest. MJT is an employee of Google and owns Alphabet stock. None of the opinions or views stated in this paper reflect the opinions or views of Google Inc.

    1. The NHS long term plan. National Health Service. 2019. URL: https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf [accessed 2024-04-25]
    2. Digital health innovation action plan. U.S. Food and Drug Administration. 2020. URL: https://www.fda.gov/media/106331/download [accessed 2024-04-25]
    3. Domingo-Lopez DA, Lattanzi G, Schreiber LHJ, Wallace EJ, Wylie R, O'Sullivan J, et al. Medical devices, smart drug delivery, wearables and technology for the treatment of diabetes mellitus. Adv Drug Deliv Rev. 2022;185:114280. [FREE Full text] [CrossRef] [Medline]
    4. Elliss-Brookes L, McPhail S, Ives A, Greenslade M, Shelton J, Hiom S, et al. Routes to diagnosis for cancer—determining the patient journey using multiple routine data sets. Br J Cancer. 2012;107(8):1220-1226. [FREE Full text] [CrossRef] [Medline]
    5. NHS Digital. 2023. URL: https://digital.nhs.uk/ndrs/data/data-outputs/cancer-data-hub/cancer-routes-to-diagnosis [accessed 2024-04-25]
    6. Scott SE, Walter FM, Webster A, Sutton S, Emery J. The model of pathways to treatment: conceptualization and integration with existing theory. Br J Health Psychol. 2013;18(1):45-65. [CrossRef] [Medline]
    7. Andersen BL, Cacioppo JT, Roberts D. Delay in seeking a cancer diagnosis: delay stages and psychophysiological comparison processes. Br J Soc Psychol. 1995;34 (Pt 1):33-52. [CrossRef] [Medline]
    8. Kummer S, Walter FM, Chilcot J, Emery J, Sutton S, Scott SE. Do cognitive heuristics underpin symptom appraisal for symptoms of cancer?: a secondary qualitative analysis across seven cancers. Psychooncology. 2019;28(5):1041-1047. [CrossRef] [Medline]
    9. Broadbent E, Petrie KJ. Symptom perception. In: Ayers S, Baum A, McManus C, Newman S, Wallston K, Weinman J, et al, editors. Cambridge Handbook of Psychology, Health and Medicine, 2nd Edition. Cambridge. Cambridge University Press; 2007:219-223.
    10. Cioffi D. Beyond attentional strategies: cognitive-perceptual model of somatic interpretation. Psychol Bull. 1991;109(1):25-41. [CrossRef] [Medline]
    11. Kolk AM, Hanewald GJFP, Schagen S, Gijsbers van Wijk CMT. A symptom perception approach to common physical symptoms. Soc Sci Med. 2003;57(12):2343-2354. [CrossRef] [Medline]
    12. Macleod U, Mitchell ED, Burgess C, Macdonald S, Ramirez AJ. Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers. Br J Cancer. 2009;101(Suppl 2):S92-S101. [FREE Full text] [CrossRef] [Medline]
    13. Zhang M, Sykes DL, Brindle K, Sadofsky LR, Morice AH. Chronic cough-the limitation and advances in assessment techniques. J Thorac Dis. 2022;14(12):5097-5119. [FREE Full text] [CrossRef] [Medline]
    14. Koo MM, Swann R, McPhail S, Abel GA, Elliss-Brookes L, Rubin GP, et al. Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study. Lancet Oncol. 2020;21(1):73-79. [FREE Full text] [CrossRef] [Medline]
    15. Germini F, Noronha N, Debono VB, Philip BA, Pete D, Navarro T, et al. Accuracy and acceptability of wrist-wearable activity-tracking devices: systematic review of the literature. J Med Internet Res. 2022;24(1):e30791. [FREE Full text] [CrossRef] [Medline]
    16. Suner S, Rayner J, Ozturan IU, Hogan G, Meehan CP, Chambers AB, et al. Prediction of anemia and estimation of hemoglobin concentration using a smartphone camera. PLoS One. 2021;16(7):e0253495. [FREE Full text] [CrossRef] [Medline]
    17. Park JH, Yang MJ, Kim JS, Park B, Kim JH, Sunwoo MH. Deep-learning-based smartphone application for self-diagnosis of scleral jaundice in patients with hepatobiliary and pancreatic diseases. J Pers Med. 2021;11(9):928. [FREE Full text] [CrossRef] [Medline]
    18. Sangers T, Reeder S, van der Vet S, Jhingoer S, Mooyaart A, Siegel DM, et al. Validation of a market-approved artificial intelligence mobile health app for skin cancer screening: a prospective multicenter diagnostic accuracy study. Dermatology. 2022;238(4):649-656. [FREE Full text] [CrossRef] [Medline]
    19. Boennelykke A, Jensen H, Østgård LSG, Falborg AZ, Hansen AT, Christensen KS, et al. Cancer risk in persons with new-onset anaemia: a population-based cohort study in Denmark. BMC Cancer. 2022;22(1):805. [FREE Full text] [CrossRef] [Medline]
    20. Stapley S, Peters TJ, Neal RD, Rose PW, Walter FM, Hamilton W. The risk of pancreatic cancer in symptomatic patients in primary care: a large case-control study using electronic records. Br J Cancer. 2012;106(12):1940-1944. [FREE Full text] [CrossRef] [Medline]
    21. Dolson CM, Harlow ER, Phelan DM, Gabbett TJ, Gaal B, McMellen C, et al. Wearable sensor technology to predict core body temperature: a systematic review. Sensors (Basel). 2022;22(19):7639. [FREE Full text] [CrossRef] [Medline]
    22. Sah RP, Sharma A, Nagpal S, Patlolla SH, Sharma A, Kandlakunta H, et al. Phases of metabolic and soft tissue changes in months preceding a diagnosis of pancreatic ductal adenocarcinoma. Gastroenterology. 2019;156(6):1742-1752. [FREE Full text] [CrossRef] [Medline]
    23. Farina GL, Orlandi C, Lukaski H, Nescolarde L. Digital single-image smartphone assessment of total body fat and abdominal fat using machine learning. Sensors (Basel). 2022;22(21):8365. [FREE Full text] [CrossRef] [Medline]
    24. Acharya S, Swaminathan D, Das S, Kansara K, Chakraborty S, Kumar RD, et al. Non-invasive estimation of hemoglobin using a multi-model stacking regressor. IEEE J Biomed Health Inform. 2020;24(6):1717-1726. [CrossRef] [Medline]
    25. Brewer HR, Hirst Y, Chadeau-Hyam M, Johnson E, Sundar S, Flanagan JM. Association between purchase of over-the-counter medications and ovarian cancer diagnosis in the Cancer Loyalty Card Study (CLOCS): observational case-control study. JMIR Public Health Surveill. 2023;9:e41762. [FREE Full text] [CrossRef] [Medline]
    26. Cromme SK, Whitaker KL, Winstanley K, Renzi C, Friedemann Smith C, Wardle J. Worrying about wasting GP time as a barrier to help-seeking: a community-based, qualitative study. Br J Gen Pract. 2016;66(648):e474-e482. [FREE Full text] [CrossRef] [Medline]
    27. Robb K, Stubbings S, Ramirez A, Macleod U, Austoker J, Waller J, et al. Public awareness of cancer in Britain: a population-based survey of adults. Br J Cancer. 2009;101(Suppl 2):S18-S23. [FREE Full text] [CrossRef] [Medline]
    28. Niksic M, Rachet B, Warburton FG, Wardle J, Ramirez AJ, Forbes LJL. Cancer symptom awareness and barriers to symptomatic presentation in England--are we clear on cancer? Br J Cancer. 2015;113(3):533-542. [FREE Full text] [CrossRef] [Medline]
    29. Jones OT, Matin RN, van der Schaar M, Bhayankaram KP, Ranmuthu CKI, Islam MS, et al. Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings: a systematic review. Lancet Digit Health. 2022;4(6):e466-e476. [FREE Full text] [CrossRef] [Medline]
    30. British association of dermatologists position statement on artificial intelligence (AI) interventions. British Association of Dermatologists. 2022. URL: https://cdn.bad.org.uk/uploads/2022/05/05083421/Position-Statement-on-Artificial-Intelligence.pdf [accessed 2024-04-25]
    31. Schroé H, Van Dyck D, De Paepe A, Poppe L, Loh WW, Verloigne M, et al. Which behaviour change techniques are effective to promote physical activity and reduce sedentary behaviour in adults: a factorial randomized trial of an e- and m-health intervention. Int J Behav Nutr Phys Act. 2020;17(1):127. [FREE Full text] [CrossRef] [Medline]
    32. Webb T, De Bruin M. Monitoring interventions. In: Hagger MS, Cameron LD, Hamilton K, Hankonen N, Lintunen T, editors. The Handbook of Behavior Change. Cambridge. Cambridge University Press; 2020:537-553.
    33. Kroenke K. Studying symptoms: sampling and measurement issues. Ann Intern Med. 2001;134(9 Pt 2):844-853. [CrossRef] [Medline]
    34. Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ Digit Med. 2022;5(1):121. [FREE Full text] [CrossRef] [Medline]
    35. Evidence standards framework for digital health technologies. National Institute for Health and Care Excellence. 2022. URL: https://www.nice.org.uk/corporate/ecd7 [accessed 2024-04-25]
    36. Walter FM, Thompson MJ, Wellwood I, Abel GA, Hamilton W, Johnson M, et al. Evaluating diagnostic strategies for early detection of cancer: the CanTest framework. BMC Cancer. 2019;19(1):586. [FREE Full text] [CrossRef] [Medline]
    37. Wang P, Kricka LJ. Current and emerging trends in point-of-care technology and strategies for clinical validation and implementation. Clin Chem. 2018;64(10):1439-1452. [FREE Full text] [CrossRef] [Medline]
    38. Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 2013;4(1):7. [FREE Full text] [CrossRef] [Medline]
    39. Cocco P, Ayaz-Shah A, Messenger MP, West RM, Shinkins B. Target product profiles for medical tests: a systematic review of current methods. BMC Med. 2020;18(1):119. [FREE Full text] [CrossRef] [Medline]
    40. Simblett S, Greer B, Matcham F, Curtis H, Polhemus A, Ferrão J, et al. Barriers to and facilitators of engagement with remote measurement technology for managing health: systematic review and content analysis of findings. J Med Internet Res. 2018;20(7):e10480. [FREE Full text] [CrossRef] [Medline]
    41. Engelhard MM, Patek SD, Sheridan K, Lach JC, Goldman MD. Remotely engaged: lessons from remote monitoring in multiple sclerosis. Int J Med Inform. 2017;100:26-31. [FREE Full text] [CrossRef] [Medline]
    42. Jonassaint CR, Shah N, Jonassaint J, De Castro L. Usability and feasibility of an mHealth intervention for monitoring and managing pain symptoms in sickle cell disease: the Sickle cell disease Mobile Application to Record symptoms via Technology (SMART). Hemoglobin. 2015;39(3):162-168. [CrossRef] [Medline]
    43. Huang F, Chang P, Hou IC, Tu MH, Lan CF. Use of a mobile device by nursing home residents for long-term care comprehensive geriatric self-assessment: a feasibility study. Comput Inform Nurs. 2015;33(1):28-36. [CrossRef] [Medline]
    44. Buchem I, Merceron A, Kreutel J, Haesner M, Steinert A. Gamification designs in wearable enhanced learning for healthy ageing. 2015. Presented at: 2015 International Conference on Interactive Mobile Communication Technologies and Learning (IMCL); November 19-20, 2015:9-15; Thessaloniki, Greece. [CrossRef]
    45. Supporting digital inclusion in health care. The King's Fund. 2022. URL: https://www.kingsfund.org.uk/projects/digital-equity [accessed 2024-04-25]
    46. Christy SM, Gwede CK, Sutton SK, Chavarria E, Davis SN, Abdulla R, et al. Health literacy among medically underserved: the role of demographic factors, social influence, and religious beliefs. J Health Commun. 2017;22(11):923-931. [FREE Full text] [CrossRef] [Medline]
    47. von Wagner C, Knight K, Steptoe A, Wardle J. Functional health literacy and health-promoting behaviour in a national sample of British adults. J Epidemiol Community Health. 2007;61(12):1086-1090. [FREE Full text] [CrossRef] [Medline]
    48. The mobile economy. GSM Association. 2022. URL: https://www.gsma.com/mobileeconomy/wp-content/uploads/2022/02/280222-The-Mobile-Economy-2022.pdf [accessed 2023-07-01]
    49. Ross J, Stevenson F, Lau R, Murray E. Factors that influence the implementation of e-health: a systematic review of systematic reviews (an update). Implement Sci. 2016;11(1):146. [FREE Full text] [CrossRef] [Medline]
    50. Dudley L, Gamble C, Preston J, Buck D, EPIC Patient Advisory Group, Hanley B, et al. What difference does patient and public involvement make and what are its pathways to impact? qualitative study of patients and researchers from a cohort of randomised clinical trials. PLoS One. 2015;10(6):e0128817. [FREE Full text] [CrossRef] [Medline]
    51. Patient and public involvement policy. National Institute for Health and Care Excellence. 2022. URL: https:/​/www.​nice.org.uk/​about/​nice-communities/​nice-and-the-public/​public-involvement/​public-involvement-programme/​patient-public-involvement-policy [accessed 2024-04-25]
    52. Altman M, Huang TTK, Breland JY. Design thinking in health care. Prev Chronic Dis. 2018;15:E117. [FREE Full text] [CrossRef] [Medline]
    53. Polhemus AM, Novák J, Ferrao J, Simblett S, Radaelli M, Locatelli P, et al. Human-centered design strategies for device selection in mHealth programs: development of a novel framework and case study. JMIR Mhealth Uhealth. 2020;8(5):e16043. [FREE Full text] [CrossRef] [Medline]
    54. Mummah SA, Robinson TN, King AC, Gardner CD, Sutton S. IDEAS (Integrate, Design, Assess, and Share): a framework and toolkit of strategies for the development of more effective digital interventions to change health behavior. J Med Internet Res. 2016;18(12):e317. [FREE Full text] [CrossRef] [Medline]
    55. Seneviratne MG, Connolly SB, Martin SS, Parakh K. Grains of sand to clinical pearls: realizing the potential of wearable data. Am J Med. 2023;136(2):136-142. [FREE Full text] [CrossRef] [Medline]
    56. Hirst Y, Stoffel ST, Brewer HR, Timotijevic L, Raats MM, Flanagan JM. Understanding public attitudes and willingness to share commercial data for health research: survey study in the United Kingdom. JMIR Public Health Surveill. 2023;9:e40814. [FREE Full text] [CrossRef] [Medline]
    57. Flanagan JM, Skrobanski H, Shi X, Hirst Y. Self-care behaviors of ovarian cancer patients before their diagnosis: proof-of-concept study. JMIR Cancer. 2019;5(1):e10447. [FREE Full text] [CrossRef] [Medline]
    58. Eisenhauer CM, Hageman PA, Rowland S, Becker BJ, Barnason SA, Pullen CH. Acceptability of mHealth technology for self-monitoring eating and activity among rural men. Public Health Nurs. 2017;34(2):138-146. [CrossRef] [Medline]
    59. Naslund JA, Aschbrenner KA, Barre LK, Bartels SJ. Feasibility of popular m-health technologies for activity tracking among individuals with serious mental illness. Telemed J E Health. 2015;21(3):213-216. [FREE Full text] [CrossRef] [Medline]
    60. Greenhalgh T, Wherton J, Papoutsi C, Lynch J, Hughes G, A'Court C, et al. Beyond adoption: a new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies. J Med Internet Res. 2017;19(11):e367. [FREE Full text] [CrossRef] [Medline]
    61. Marlow LAV, Schmeising-Barnes N, Brain K, Duncombe S, Robb KA, Round T, et al. Multi-cancer early detection tests for cancer screening: a behavioural science perspective. Lancet Oncol. 2022;23(7):837-839. [CrossRef] [Medline]
    62. Barnett KN, Weller D, Smith S, Steele RJ, Vedsted P, Orbell S, et al. The contribution of a negative colorectal screening test result to symptom appraisal and help-seeking behaviour among patients subsequently diagnosed with an interval colorectal cancer. Health Expect. 2018;21(4):764-773. [FREE Full text] [CrossRef] [Medline]
    63. Cancer moonshot. National Cancer Institute. 2022. URL: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative [accessed 2024-04-25]
    64. NHS long term plan ambitions for cancer. NHS England. 2019. URL: https://www.england.nhs.uk/cancer/strategy/ [accessed 2024-04-25]

    ‎
    FDA: Food and Drug Administration
    NICE: National Institute of Health and Care Excellence
    NHS: National Health Service
    mHealth: mobile health

    Edited by T de Azevedo Cardoso; submitted 08.09.23; peer-reviewed by Y Hirst, H Brewer; comments to author 21.02.24; accepted 12.03.24; published 20.05.24.

    Copyright

    ©Suzanne E Scott, Matthew J Thompson. Originally published in JMIR Cancer (https://cancer.jmir.org), 20.05.2024.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cancer, is properly cited. The complete bibliographic information, a link to the original publication on https://cancer.jmir.org/, as well as this copyright and license information must be included.